INTRODUCTION
============

Single nucleotide polymorphisms (SNPs), DNA variations in a single nucleotide position are often genetic determinants of disease; therefore, they have become predominant genetic markers in genome research. The labor intensive field of SNP identification and detection has been fueled by numerous intellectual and financial resources ([@B1]). While development of high and low multiplex methods ([@B2]) has received considerable attention and effort, there is currently a lack of much needed intermediate systems.

Recent technological advances have provided platforms (Affymetrix and Illumina Inc.) that allow parallel analysis of potentially millions of SNPs, making large-scale association studies a reality ([@B3],[@B4]). However, genome-wide association analysis (GWA) relies on multiple time intensive replication screens using only a small subset of SNPs, those with high *P*-values. Moreover, clinical diagnostic testing will require identification of hundreds of SNPs, not millions. Therefore, alternative methods that are flexible, fast and inexpensive are urgently needed ([@B5; @B6; @B7; @B8]).

Primer extension on microarrays, first reported over a decade ago ([@B9]), has become mainstream technology ([@B10]). Originally it comprised of four steps: (i) targeted DNA amplification; (ii) fragmentation and array-based hybridization; (iii) enzymatic single-base extension (SBE) on the array and (iv) signal detection ([@B11]). Considering the capability of PCR amplicon detection in a single reaction tube is routinely 2--10 ([@B5],[@B6]) and maximally 48 ([@B7]) amplicons per reaction, reliable multiplex PCR template amplification remains challenging ([@B12]).

Here, we report an improved arrayed primer extension genotyping method (APEX-2) capable of identifying hundreds of SNPs and mutations in parallel using efficient homogeneous multiplex PCR (up to 640-plex) and SBE on microarrays ([Figure 1](#F1){ref-type="fig"}). In the present report, we outline and justify the principle of the APEX-2 reaction, describe APEX-2 primer construction and validate the applicability of the APEX-2 principle using 640-plex amplification and genotyping. Figure 1.The APEX-2 principle. (**A**) APEX-2 primers (APEX-2 primers 1 and 2) bind to specific genomic DNA sequences immediately upstream of the position of interest. After primer extension, the synthesized sequence contains the complement of the respective APEX-2 primer and the position of interest (SNP/mutation). The second cycle of primer extension generates a complement of the universal sequence. (**B**) The universal primer hybridizes to the 3′ end of the previously generated product during template amplification, followed by genotyping on the microarray. (**C**) APEX-2 primers have a 5′-amino modification, enabling spotting and immobilization on the microarray. The purified phase 2 PCR product hybridizes to the immobilized APEX-2 primers. Genotyping is then performed as a four-color single-base extension reaction.

MATERIALS AND METHODS
=====================

Oligonucleotide design and synthesis
------------------------------------

SNP-specific primers were designed by retrieval of 50-bp regions flanking either side of the SNP genomic sequence. A 50-bp reverse complement of the 3′→5′ strand was generated, and truncated at the 5′ end until an optimal melting temperature (57--62°C) was achieved. Melting temperature was calculated using a formula from *Primer3* software ([@B13]). Primer pair specificity was verified using *GenomeTester 1.3* ([@B14]), which predicted generation of a single product (up to 1000 bp) per primer pair based on the human genome. Primer sequences were further assessed for the presence of SNPs using *SNPmasker* software ([@B15]). APEX-2 primers were generated upon addition of a universal sequence (5′-GATCAGGCGTCTGTCGTGCTC-3′) to the 5′ end of each SNP-specific primer. APEX-2 primers were then amino modified at the 5′ end (for sequence see [Table 1](#T1){ref-type="table"}, small letters), attached via a linker, to enable primer immobilization on a solid surface. Oligonucleotides \[de-salted, 100 pmol/µl in TE (10 mM Tris--HCl pH 8.0, 1 mM EDTA)\] were purchased from Metabion International AG, Martinsried, Germany and stored at −20°C. All oligonucleotides were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI) to control the length and purify. Quality controls of lyophilized universal primers were verified by DMT monitoring (Metabion Int. AG). Prior to use, lyophilized probes were dissolved in distilled water (500 pmol/µl). Table 1.Details of APEX-2 primers for this study (5 examples)Primer nameModificationSequence (5′--3′)*T*m (°C) specific*T*m (°C) fullPrimer Length1_F\_rs3760629C6-Aminolink`gatcaggcgtctgtcgtgctcAAAGAGTTGTCTTAGGAAGAGGGGTCAGA`59.584501_R\_rs3760629C6-Aminolink`gatcaggcgtctgtcgtgctcCTTTTGCCCAGCACCCTTGTC`56.684422_F\_rs204467C6-Aminolink`gatcaggcgtctgtcgtgctcCCCCGTCTCTTCTGTCTTTGTGAGTC`59.685472_R\_rs204467C6-Aminolink`gatcaggcgtctgtcgtgctcCAGATGGGGAGAGAGAGGAGGG`57.486433_F\_rs10413089C6-Aminolink`gatcaggcgtctgtcgtgctcGCAGTTTGTATTTATAGCTGAGAGCGCAG`59.384503_R\_rs10413089C6-Aminolink`gatcaggcgtctgtcgtgctcCAGCCTCACTGCAACCCCA`56.484404_F\_rs5127C6-Aminolink`gatcaggcgtctgtcgtgctcGGCACTGCTTTTCTGAGGACTCAAG`58.584464_R\_rs5127C6-Aminolink`gatcaggcgtctgtcgtgctcGTCAGCCCCTCCATCTTGGC`57.285415_F\_rs16979595C6-Aminolink`gatcaggcgtctgtcgtgctcCATAAGCCTGCAGAGCTCTGACCA`58.784455_R\_rs16979595C6-Aminolink`gatcaggcgtctgtcgtgctcTCATGGCTGCTGGGCCTTC`578440

Multiplex PCR with specific primers
-----------------------------------

Genomic sample DNA was relatively intact and free of PCR inhibitors, including high concentrations of heme compounds and chelating agents. Genomic DNA (50--100 ng/µl in TE buffer) was denatured for 5 min at 98°C, and then cooled to 4°C prior to PCR analysis. Multiplex PCR reactions had a final volume of 15 µl, which contained PCR buffer \[60 mM Tris--HCl pH 8.3, 60 mM KCl, 15 mM (NH~4~)~2~SO~4~\], 0.2 mM of each dNTP (*N* = G, C, A, T) (Fermentas, Vilnius, Lithuania), 5.75 mM MgCl~2~, 2 U TrueStart™ *Taq* DNA polymerase (Fermentas), 30 nM of each SNP-specific primer (Metabion Int. AG) and not \< 150 ng denatured genomic DNA. PCR amplification was conducted in TProfessional Basic (Biometra, Göttingen, Germany), PTC-200 (MJ Research, Waltham, MA, USA) or PIKO (Finnzymes, Espoo, Finland) thermocyclers under the following amplification conditions: 98°C/1 min (initial denaturation); 25 cycles of 95°C/15 s (denaturation), 63°C/1 min, 64°C/1 min, 65°C/1 min, 66°C/1 min, 67°C/15 s, 68°C/15 s (annealing) and 72°C/15 s (extension). PCR amplification conditions using a GeneAmp® PCR System 9700 thermocycler (Applied Biosystems, Foster City, CA, USA) differed and are as follows: 98°C/45 s (initial denaturation); 25 cycles of 95°C/20 s (denaturation), 60°C/2 min (annealing) and 72°C/20 s (extension). The time between annealing and extension steps using the GeneAmp® PCR System 9700 thermocycler was approximately 6 min, as ensured by a 3% ramp speed.

Universal primer-based amplification and product purification
-------------------------------------------------------------

A nested PCR approach was conducted using universal primers. The final volume of the phase 2 PCR reaction was 150 µl, and contained 15 µl of the phase 1 PCR product, PCR buffer \[80 mM Tris pH 9.5, 20 mM (NH~4~)~2~SO~4~, 0.2% w/v Tween-20\] (Solis Biodyne, Tartu, Estonia), 3 mM dNTPs (Fermentas), 3 mM MgCl~2~, 15 U HOT FIREPol® *Taq* DNA polymerase (Solis Biodyne), 40 µM universal primer (5′-GATCAGGCGTCTGTCGTGCTC-3′) (Metabion Int. AG). PCR amplification was conducted in a TProfessional Basic thermocycler under the following conditions: 95°C/15 min (enzyme activation and initial denaturation); 35 cycles of 95°C/30 s (denaturation), 54°C/30 s (annealing) and 72°C/5 s (extension). To confirm amplicon size, 1 µl of the PCR product was visualized on a 2% TBE agarose gel. PCR products from universal primer-based amplification were purified using NucleoSpin® Extract II (Macherey-Nagel, Düren, Germany) single columns \[eluted in 28 µl buffer (5 mM Tris, pH 8.5)\], extract binding plates or the MinElute PCR Purification kit (Qiagen, Hilden, Germany) using modified protocols. Briefly, 150 µl phase 2 PCR product and 300 µl NT buffer, mixed in a Round-well Block (Macherey-Nagel), were transferred to an extract binding plate, centrifuged for 2 min at 4600*g*, washed twice with 300 µl NT3 and centrifuged for 3 min at 4600*g*. The dried extract binding plate was then placed on a Round-well Block, eluted with 37 µl NE and centrifuged 2 min at 4600*g*. Modifications to the MinElute PCR Purification kit protocol include: addition of 2 µl of 5.4 M sodium acetate (pH 5.0), to guarantee an optimum pH, to the column containing 600 µl binding buffer and 150 µl of PCR product. Products were eluted with 28 µl EB buffer (Qiagen).

Oligonucleotide microarray
--------------------------

Sense and antisense APEX-2 primers were designed and constructed with a 5′-C6-amino linker, as described earlier. Primer sequences were derived from the reported human genome (NCBI 36, Oct 2005). Oligonucleotides were immobilized on SAL (aminosilane with linker) microarray slides (24 × 60 mm^2^) in predetermined positions (Asper Biotech, Ltd., Tartu, Estonia, [www.asperbio.com](www.asperbio.com)). Prior to spotting, primers (50 µM in 100 mM carbonate buffer, pH 9.0) were immobilized onto the activated array surface using the ChipWriter™ Pro System (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Postspotting, slides were blocked with a 1% NH~4~OH solution and stored at 4°C.

Single-base extension and signal detection
------------------------------------------

Prior to primer extension with dideoxynucleotides, purified PCR products were treated with shrimp alkaline phosphatase (SAP) in order to eliminate residual active deoxynucleotides. Briefly, 3 µl of concentrated APEX reaction buffer (500 mM Tris--HCl pH 9.5, 85 mM MgCl~2~, 100 mM KCl), 0.25 U SAP (Fermentas) and 26 µl of purified PCR product were incubated at 37°C for 10 min, followed by SAP inactivation at 95°C for 5 min. Prior to SBE, templates were denatured on the array at 95°C for 5 min. SBE components were then added to the denatured PCR product, for a final reaction volume of 30 µl, which included: 1.5 µM of each dideoxynucleotide mixture, Cy3-ddATP, Cy5-ddGTP, Texas Red-ddCTP (Perkin Elmer Life Science, Waltham, Massachusetts, USA), Fluoresceine-12-ddUTP (ENZO Life Science, Farmingdale, NY, USA); 4.8 U of ThermoSequenase™ (GE Healthcare, Waukesha, WI, USA); and 1 µl enzyme dilution buffer (GE Healthcare). The SBE reaction mixture was applied to arrays prewarmed on a heated plate, then covered with LifterSlip™ (22 × 25 mm^2^, Erie Scientific Company, Portsmouth, NH, USA). Hybridization and APEX-2 reactions were performed at 58°C for 20 min and terminated by washing at 95°C for 1 min with distilled water, 3 min in 0.3% Alconox® solution (Alconox, White Plains, NY, USA), and twice at 95°C for 1 min with distilled water to remove the Alconox. To prevent photobleaching, a drop of Atlas Antifade (BioAtlas, Tartu, Estonia) was applied to the microarray, which was then coverslipped. Slide hybridization was detected by the Genorama™ Imaging System (Asper Biotech Ltd); and loci of interest were identified by Genorama™ Genotyping Software 4.2 Package (Asper Biotech Ltd) using clustered signal patterns from the dbSNP database (release 125) as a statistical reference.

RESULTS
=======

APEX-2 reaction principle
-------------------------

[Figure 1](#F1){ref-type="fig"} is a schematic diagram illustrating the principles of multiplex PCR and SBE on oligoarrays (Patent application PCT/EE2007/000003). Oligonucleotides are immobilized to the microarray via primer 5′ amino modification, a convenient procedure facilitating a stable covalent bond to the array surface with no observed negative effects in subsequent PCR reactions. The amino-modified APEX-2 oligonucleotides immobilized on the microarray then site-specifically anneal to the denatured genomic DNA, binding just upstream of the position of interest (SNP or mutation), followed by primer elongation (Phase 1). Phase 1 generates a synthesized sequence that contains a nucleotide complementary to the position of interest. During phase 2, the SBE template is produced with multiplex PCR using universal primers. While the final reaction volume of phase 1 PCR is 15 µl, phase 2 PCR requires a final volume of 150 µl to insure sufficient amplicon quantity (total yield of 15 µg, data not shown) for microarray visualization. Detection on the microarray requires both the immobilized amino-modified APEX-2 oligonucleotide probes (positions on array are fixed during spotting), and the SBE template. Therefore, the APEX-2 method uses two site-specific oligonucleotides per position of interest, used both in amplification and detection on the microarray.

APEX-2 primer construction
--------------------------

The APEX-2 primer is composed of three regions: (i) a region complementary to the genomic DNA sequence downstream of the point of interest; (ii) a universal sequence, enabling equal amplification of all phase 1 amplicons and (iii) a chemical modification, a 5′ amino-modified primer with a C6 linker, immobilizing the primer on the microarray ([Table 1](#T1){ref-type="table"}, modification and sequence columns). The length of the universal tail, common to all APEX-2 primers, is 21 bp and contains no binding sites complementary to the human genome. The length of the complementary region ranges from 18 to 50 bp, which is dependent on melting temperature (57--62°C). According to reaction principles, phase 1 multiplex polymerization (minimum two cycles) generates amplicons containing complementary sequence to the universal tail; using primers designed to this sequence, all phase 1 elongated products can be amplified and the position of interest studied. Final phase 2 double-stranded PCR products contain the position(s) of interest located between sense and antisense APEX-2 primer sequences. Due to the small size of phase 2 PCR products (79--130 bp, [Figure 2](#F2){ref-type="fig"}A) product fragmentation prior to microarray hybridization is unnecessary. Figure 2.Generation of specific products using multiplex PCR. (**A**) Product quantity is visible as duplicates after phase 1 PCR, sampled in two cycle increments (cycles 16--24). Representative images include marker (M) and gel band intensities corresponding to multiplex PCR products. DNA was visualized using the Agilent DNA 1000 LabChip after Exonuclease I treatment to remove primers. (**B**) The product band after universal primer amplification and column purification.

Assay validation
----------------

To assess the performance of the APEX-2 assay, APEX-2 primer pairs were designed against 821 polymorphic loci from 40 different genes spanning the entire human genome. SNPs were selected according to linkage disequilibrium patterns of the HapMap CEU reference population. Individual tagSNPs were identified by applying Carlson\'s algorithm \[*r*^2^ threshold = 0.8, minor allele frequency (MAF) ≥ 5%\] ([@B16]); and, genotyping accuracy was assessed using 17 family trios. After quality control, 22% of SNPs (181 of 821) were discarded due to insufficient quality parameters: 94 SNPs had low call rates (\< 95%), 50 SNPs failed genotype calling (false signal in an unexpected position), 31 SNPs were not in Hardy--Weinberg equilibrium and six SNPs displayed Mendelian inheritance errors.

The validity of the APEX-2 method using screened SNPs (640 of 821) was tested with 205 individual DNAs (as population control samples) derived from the Estonian Genome Project, University of Tartu, by measuring call rate (99.86%) and reproducibility ([Table 2](#T2){ref-type="table"}). Reproducibility was determined by independently genotyping randomly chosen individuals (*n* = 9) five times. Missing calls occurred in 24 positions (99.91%) distributed equally over the examined DNAs. Table 2.Quality parameters for APEX-2 assayParameterValue (%)CountsAssay success rate78640 of 821Call rate99.86131.019 of 131.200Reproducibility99.9128.776 of 28.800Concordance rate with other method98.553195 of 3242

Concordance between Illumina (*HumanHapCNV370-Duo v1.0 BeadChips*) and APEX-2 genotype methods was determined using 173 SNPs in 19 individuals (3287 genotypes in total). The call rates of both methods, the Illumina and APEX-2, in those positions were 99.33 and 99.24%, respectively. Therefore, 22 positions genotyped with Illumina and 25 positions genotyped with APEX-2 were incomparable due to missing calls. Two positions failed with both platforms. Consequently, for the concordance evaluations stage the input number of genotypes remained at 3242 of which 3195 genotypes matched (47 genotyping errors). Hence, we detected 98.55% concordance rate between two platforms ([Table 2](#T2){ref-type="table"}). We detected five SNPs, in case of which the genotyping results did not match with three to four DNA samples between the used platforms. Thirty-four percent (16 of 47) of errors occurred in two DNAs. To analyze discordant genotype calls with a third method, we chose four (out of 29) SNPs in case of which the polymorphic position located at the restriction cleavage site (rs615098 *TaiI*, rs4940086 *BseGI*, rs1064875 *SsiI*, rs11119344 *TaqI*). By taking into account the number of DNAs having unmatched genotypes between the compared methods, altogether we analyzed 10 out of 47 discordant calls ascertained. The restriction results showed that APEX-2 had generated six errors, Illumina platform two mistakes and in case of two cases the calls of both methods differed from the results gained from the restriction analysis. We also scrutinized all 47 discordant positions manually and detected 20 APEX-2 calls in case of which, although a matching genotype with Illumina was visible, it remained automatically undetectable (due to the low signal-to-noise ratio).

DISCUSSION
==========

We have developed a multiplex genotype and mutation detection platform based upon simultaneous amplification of multiple loci in a single tube reaction, and successive use of reaction products in microarray SBE detection, eliminating the need for additional primers. The APEX-2 approach is an immense improvement to current PCR-based approaches, increasing multiplexing capacity by 10- to 100-fold ([@B8],[@B17]) reliability, as well as time and cost effectiveness. The foundation of these advancements include: (i) generation of short products (∼100 bp) due to the close proximity of hybridizing APEX-2 primers (primers are only separated by the position of interest) and (ii) incorporation of the universal primer in the APEX-2 oligonucleotide sequence, allowing phase 2 PCR amplification under optimal conditions, which is not feasible with PCR primers containing unique sequences.

A comparison of APEX-2 with its predecessor, APEX ([@B11]), illustrates the technical benefits associated with multiplex PCR, which includes faster analysis and cost effectiveness due to a reduction in labor-intensive steps. The first step of APEX is amplification of genomic regions adjacent to the SNP to produce sufficient template for detection. Comparatively, after phase 1 of APEX-2, the SNP has already been incorporated into the template DNA; and phase 2 amplification produces sufficient DNA for microarray SBE detection. While other low to medium throughput APEX, similar techniques are currently being employed, they require additional steps circumvented by the APEX-2 method, including enzymatic treatment of PCR generated probes to remove unincorporated deoxynucleotides and primers, and subsequent SBE analysis via microarray ([@B18]), electrophoresis (SNaPshot from Applied Biosystems®) or mass differences (iPLEX from Sequenom®). Further, APEX-2 differs from well-known molecular inversion probe (MIP) ([@B19]) and Illumina Golden Gate reaction principles in some essential aspects: APEX-2 primers are linear oligonucleotides that neither contains cleavage sites nor *tag-ctag* system sequences; and during APEX-2 detection, fluorescently labeled dideoxynucleotides are enzymatically incorporated into the immobilized primer sequence through a primer extension reaction.

Four core factors to the APEX-2 design increase signal specificity and strength compared with alternative techniques: (i) APEX-2 primers anneal to both strands of genomic DNA within 26 bp up- and down-stream of the position of interest; (ii) universal primer PCR amplification favors a high yield of short products (∼100 bp); (iii) the universal primer has no homologous binding sites to published human genome sequences (prior to December 2007). Therefore, templates lacking the universal primer sequence will not be amplified and (iv) prior to SBE, the probe-target hybridization control step on a solid surface ensures a high signal-to-noise ratio. While primer specificity is assured by a short region of interaction with genomic DNA (median of 26 bp, [Figure 1](#F1){ref-type="fig"}), microarray hybridization involves a longer region of interaction (median 48 bp); therefore, microarray specificity is influenced by probe length and distance from the 3′end of the primer ([@B20]), as well as distance between the complementary region and the solid surface of the array. Optimization of these parameters may improve reaction kinetics and thereby favor higher signal intensities ([@B21]).

In addition to detection of single nucleotide variations, APEX-2 applications also include detection of short (up to 25 bp) deletion or insertion regions ([Figure 3](#F3){ref-type="fig"}A). For example, we have successfully analyzed a marker (rs3908) on Y-chromosome ([Figure 3](#F3){ref-type="fig"}B, deletion). Further, if positions of interest are in close proximity to one another and a polymorphic nucleotide is included in the primer sequence, then distinct APEX-2 oligonucleotides can be designed. The exact design of primers can differ from the principle outlined in [Figure 3](#F3){ref-type="fig"}C depending on sequence context. Analyzing mitochondrial positions, which frequently situate close together, one polymorphic site may locate under primer-binding region of the other sequence variation and cause failure during hybridization. As a solution, APEX-2 offers the opportunity to design primers so that system amplifies and detects both genetic markers in one reaction using one pair of oligonucleotides ([Figure 3](#F3){ref-type="fig"}D). Figure 3.The principle of APEX-2 primer design for insertion/deletion analysis (**A**), deletion detection with an exact sequence and SBE signals on microarray (**B**) and analysis in case the positions lie close together (**C**). Mitochondrial positions 14893 (red) and 14798 (blue) are separated by 4 nt and both are detected using one pair of oligonucleotides (**D**).

Despite the significant advantages of APEX-2, obstacles remain minimal. The required quantity of genomic DNA per position of interest for APEX-2 (0.3 ng) is less than other multiplex PCR-based genotyping methods ([@B17]) and comparable to the iPLEX assay (0.2--0.3 ng) ([@B6]), MIP probe (0.17 ng) ([@B22]) and Illumina Golden Gate assay (0.3--1.4 ng). Although, the experimental design reported here was limited to 640-plex, we do not foresee any confounding obstacles in increasing the multiplex PCR level as large as 1500-plex. Conversely, smaller marker selections (10, 50, 100 and 300-plex assays) have also been successful (data not shown).

While the potential to genotype more than 600 SNPs/mutations simultaneously on custom-made microarrays may generate new opportunities in the fields of replication and whole-genome screening using commercial platforms, the flexible and medium-scale APEX-2 method may provide a vehicle for clinical disease identification as well as facilitate the involvement of thousands of individuals in research, molecular diagnostics and forensic analysis.
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